Loading clinical trials...
Loading clinical trials...
A Worldwide, Phase I, Dose-Escalating Study of Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Healthy Adults
Conditions
Interventions
V520
Comparator: V520 (1x10^9 vp/d)
+2 more
Start Date
June 1, 2003
Primary Completion Date
October 1, 2006
Completion Date
February 1, 2011
Last Updated
February 27, 2015
NCT06694805
NCT04142047
NCT07055451
NCT07428330
NCT07225530
NCT05897099
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions